General Information of Drug Metabolite (DM) (ID: DM014852)
DM Name
ASA
Synonyms
aspirin|ACETYLSALICYLIC ACID|50-78-2|2-Acetoxybenzoic acid|2-(Acetyloxy)benzoic acid|O-Acetylsalicylic acid|Acetylsalicylate|o-Acetoxybenzoic acid|Acylpyrin|Easprin|Ecotrin|Salicylic acid acetate|Acenterine|Acetophen|Acetosal|Colfarit|Polopiryna|Acetosalin|Aspirdrops|Enterosarein|Pharmacin|Premaspin|Salcetogen|Aceticyl|Acetonyl|Acetylin|Acidum acetylsalicylicum|Benaspir|Empirin|Endydol|Measurin|Rhodine|Saletin|Temperal|Ecolen|Rheumintabletten|Solprin acid|o-Carboxyphenyl acetate|Enterosarine|Acetisal|Acetylsal|Aspirine|Bialpirina|Bialpirinia|Claradin|Clariprin|Entericin|Enterophen|Globentyl|Micristin|Neuronika|Salacetin|Solpyron|Acesal|Acisal|Asagran|Asteric|Cemirit|Decaten|Duramax|Extren|Globoid|Helicon|Idragin|Levius|Pirseal|Rhonal|Solfrin|Adiro|Aspec|Aspro|Novid|Yasta|Acetosalic acid|Benzoic acid, 2-(acetyloxy)-|2-acetyloxybenzoic acid|Spira-Dine|Bi-prin|Acimetten|Bufferin|Delgesic|Entrophen|Acetilum acidulatum|Acetilsalicilico|2-Carboxyphenyl acetate|Dolean pH 8|Triple-sal|ZORprin|Contrheuma retard|XAXA|Acido acetilsalicilico|Acide acetylsalicylique|Endosprin|Persistin|A.S.A. empirin|ASA|8-hour Bayer|Acetysal|Kapsazal|Asatard|Durlaza|Bayer|Ronal|Acetylsalicylsaure|Rheumin tabletten|2-Acetoxybenzenecarboxylic acid|Acetylsalycilic acid|Asaphen|Istopirin|Magnecyl|Medisyl|Polopirin|Tasprin|Bayer Buffered|acetyl salicylate|Aspro Clear|Coricidin D|Bayer Plus|Aspir-Mox|Nu-seals aspirin|Salicylic acid, acetate|Acido O-acetil-benzoico|aspirin (acetylsalicylic acid)|Kyselina acetylsalicylova|Durlaza ER|Acetylsalicylsaeure|Azetylsalizylsaeure|SP 189|St. Joseph Aspirin for Adults|A.S.A.|St. Joseph|Aspirina 03|Kyselina 2-acetoxybenzoova|AC 5230|Acetylsalicyclic acid|acetyl salicylic acid|Bayer Aspirin 8 Hour|S-211|Acetylsalicylicum acidum|Aspropharm|Cardioaspirin|CCRIS 3243|HSDB 652|Asprin|CHEBI:15365|Bayer Children's Aspirin|o-(Acetyloxy)benzoic acid|Acetylsalicylsaure [German]|ECM|EINECS 200-064-1|UNII-R16CO5Y76E|Bay E4465|NSC 27223|NSC-27223|acide 2-(acetyloxy)benzoique|Bayer Extra Strength Aspirin for Migraine Pain|Acetard|NSC-406186|Empirin with Codeine|BRN 0779271|R16CO5Y76E|DTXSID5020108|Acide acetylsalicylique [French]|Acido acetilsalicilico [Italian]|2-(acetyloxy)benzoate|AI3-02956|Aspirin [BAN:JAN]|Kyselina acetylsalicylova [Czech]|Acido O-acetil-benzoico [Italian]|Kyselina 2-acetoxybenzoova [Czech]|benzoic acid, 2-acetoxy-|BAY1019036|Aspirin [USP:BAN:JAN]|Bayer Enteric 325 mg Regular Strength|Bayer Enteric 81 mg Adult Low Strength|Bayer Enteric 500 mg Arthritis Strength|DTXCID50108|Acetylsalicylic acid (who-ip)|AXOTAL COMPONENT ASPIRIN|AZDONE COMPONENT ASPIRIN|CODOXY COMPONENT ASPIRIN|AGGRENOX COMPONENT ASPIRIN|Aspirin form II|DUOCOVER COMPONENT ASPIRIN|EXCEDRIN COMPONENT ASPIRIN|FIORINAL COMPONENT ASPIRIN|NORGESIC COMPONENT ASPIRIN|PERCODAN COMPONENT ASPIRIN|Q-GESIC COMPONENT ASPIRIN|ROXIPRIN COMPONENT ASPIRIN|VICOPRIN COMPONENT ASPIRIN|YOSPRALA COMPONENT ASPIRIN|DUOPLAVIN COMPONENT ASPIRIN|EC 200-064-1|EQUAGESIC COMPONENT ASPIRIN|INVAGESIC COMPONENT ASPIRIN|LANORINAL COMPONENT ASPIRIN|MICRAININ COMPONENT ASPIRIN|ROBAXISAL COMPONENT ASPIRIN|component of Midol|ASPIRIN COMPONENT OF AXOTAL|ASPIRIN COMPONENT OF AZDONE|ASPIRIN COMPONENT OF CODOXY|acetylsalisylic acid|4-10-00-00138 (Beilstein Handbook Reference)|NSC27223|ORPHENGESIC COMPONENT ASPIRIN|ASPIRIN COMPONENT OF AGGRENOX|ASPIRIN COMPONENT OF DUOCOVER|ASPIRIN COMPONENT OF EXCEDRIN|ASPIRIN COMPONENT OF FIORINAL|ASPIRIN COMPONENT OF NORGESIC|ASPIRIN COMPONENT OF PERCODAN|ASPIRIN COMPONENT OF Q-GESIC|ASPIRIN COMPONENT OF ROXIPRIN|ASPIRIN COMPONENT OF VICOPRIN|ASPIRIN COMPONENT OF YOSPRALA|SYNALGOS-DC COMPONENT ASPIRIN|component of Synirin|ASPIRIN COMPONENT OF DUOPLAVIN|ASPIRIN COMPONENT OF EQUAGESIC|ASPIRIN COMPONENT OF INVAGESIC|ASPIRIN COMPONENT OF LANORINAL|ASPIRIN COMPONENT OF MICRAININ|ASPIRIN COMPONENT OF ROBAXISAL|NSC406186|component of Zactirin|MEPRO-ASPIRIN COMPONENT ASPIRIN|PERCODAN-DEMI COMPONENT ASPIRIN|PRAVIGARD PAC COMPONENT ASPIRIN|SOMA COMPOUND COMPONENT ASPIRIN|ASPIRIN COMPONENT OF ORPHENGESIC|component of Coricidin|component of Persistin|component of Robaxisal|o-Acetoxybenzoate|ASPIRIN COMPONENT OF SYNALGOS-DC|DARVON COMPOUND COMPONENT ASPIRIN|INVAGESIC FORTE COMPONENT ASPIRIN|TALWIN COMPOUND COMPONENT ASPIRIN|NCGC00015067-04|ACIDUM ACETYLSALICYLICUM (WHO-IP)|ASPIRIN COMPONENT OF MEPRO-ASPIRIN|ASPIRIN COMPONENT OF PERCODAN-DEMI|ASPIRIN COMPONENT OF PRAVIGARD PAC|ASPIRIN COMPONENT OF SOMA COMPOUND|ORPHENGESIC FORTE COMPONENT ASPIRIN|ASPIRIN COMPONENT OF DARVON COMPOUND|ASPIRIN COMPONENT OF INVAGESIC FORTE|ASPIRIN COMPONENT OF TALWIN COMPOUND|ASPIRIN (MART.)|ASPIRIN [MART.]|ASPIRIN COMPONENT OF ORPHENGESIC FORTE|component of Ascodeen-30|WLN: QVR BOV1|CARISOPRODOL COMPOUND COMPONENT ASPIRIN|AcetylsalicylicAcid|ASPIRIN COMPONENT OF CARISOPRODOL COMPOUND|CLOPIDOGREL/ACETYLSALICYLIC ACID COMPONENT ASPIRIN|component of Darvon with A.S.A|Aloxiprimum|Aspalon|ASPIRIN COMPONENT OF CLOPIDOGREL/ACETYLSALICYLIC ACID|Nu-seals|component of St. Joseph Cold Tablets|CAS-50-78-2|Acetoxybenzoic acid|Acetysalicylic acid|AIN|SMR000059138|Ascoden-30|Acid, Acetylsalicylic|SR-01000075668|Cardioaspirina|Acetyonyl|Angettes|Asacard|Ascolong|Aspirina|Cardiprin|Claragine|Colsprin|Encaprin|Miniasal|Pravigard|Salospir|Acesan|Toldex|Acetylsalisylsyre|Azetylsalizylsaure|ASA Empirin|1oxr|2-Acetoxybenzoate|O-acetylsalicylsyre|Aspirin,(S)|Aspalon (JAN)|Durlaza (TN)|Easprin (TN)|MFCD00002430|acetyl-salicylic acid|VAZALORE|acetyl salicyclic acid|o-(Acetyloxy)benzoate|Percodan (Salt/Mix)|Ascriptin (Salt/Mix)|Micrainin (Salt/Mix)|2-acetoxy benzoic acid|RHODINE NC RP|Spectrum_001245|2-Acetylsalicyclic acid|Acide acetyl salicylique|ASPIRIN [VANDF]|ASPIRIN [HSDB]|Salicylic acid, acetyl-|ASPIRIN [JAN]|ASPIRIN [MI]|CHEMBL25|Spectrum2_001899|Spectrum3_001295|Spectrum4_000099|Spectrum5_000740|Aspirin (JP17/USP)|Lopac-A-5376|Salycylacetylsalicylic acid|ASPIRIN [USP-RS]|D0GY5Z|D0XB8R|Epitope ID:114151|Percodan Demi (Salt/Mix)|Soma Compound (Salt/Mix)|Acetylsalicylic acid, 99%|cid_2244|Pravigard PAC (Salt/Mix)|SCHEMBL1353|2-(Acetyloxy)-benzoic acid|A.S.A|Bay-e-4465|Lopac0_000038|KBioGR_000398|KBioGR_002271|KBioSS_001725|KBioSS_002272|MLS001055329|MLS001066332|MLS001336045|MLS001336046|ASPIRIN [ORANGE BOOK]|BIDD:GT0118|DivK1c_000555|SPECTRUM1500130|acetylsalicylic acid (aspirin)|SPBio_001838|Acetylsalicylic acid, >=99%|GTPL4139|ASPIRIN [USP MONOGRAPH]|O-Acetylsalicylic acid; Aspirin|BDBM22360|HMS501L17|KBio1_000555|KBio2_001725|KBio2_002271|KBio2_004293|KBio2_004839|KBio2_006861|KBio2_007407|KBio3_002149|KBio3_002751|Empirin with Codeine (Salt/Mix)|Acetylsalicylic acid, >=99.0%|cMAP_000006|component of Zactirin (Salt/Mix)|NINDS_000555|HMS1920E13|HMS2090G03|HMS2091K13|HMS2233L18|HMS3260G17|HMS3372N15|HMS3656N14|HMS3715P19|HMS3866L03|HMS3885G03|Pharmakon1600-01500130|ACETYLSALICYLIC ACID [INCI]|BCP21790|STR01551|ACETYLSALICYLIC ACID; ASPIRIN|Tox21_110076|Tox21_202117|Tox21_300146|Tox21_500038|CCG-39490|LS-143|NSC755899|s3017|STL137674|ACETYLSALICYLIC ACID [WHO-DD]|AKOS000118884|component of Ascodeen-30 (Salt/Mix)|Tox21_110076_1|ACETYLSALICYLIC ACID [EMA EPAR]|ACETYLSALICYLICUM ACIDUM [HPUS]|CS-2001|CS-T-01103|DB00945|LP00038|NSC-755899|PL-2200|SDCCGSBI-0050027.P005|BAY-1019036|IDI1_000555|ACETYLSALICYLIC ACID [GREEN BOOK]|Acetylsalicylic acid, analytical standard|NCGC00015067-01|NCGC00015067-02|NCGC00015067-03|NCGC00015067-05|NCGC00015067-06|NCGC00015067-07|NCGC00015067-08|NCGC00015067-09|NCGC00015067-10|NCGC00015067-11|NCGC00015067-12|NCGC00015067-13|NCGC00015067-14|NCGC00015067-24|NCGC00015067-26|NCGC00090977-01|NCGC00090977-02|NCGC00090977-03|NCGC00090977-04|NCGC00090977-05|NCGC00090977-06|NCGC00090977-07|NCGC00254034-01|NCGC00259666-01|NCGC00260723-01|Aspirin, meets USP testing specifications|HY-14654|NCI60_002222|ACETYLSALICYLIC ACID [EP MONOGRAPH]|SBI-0050027.P004|UNM-0000306102|component of Darvon with A.S.A (Salt/Mix)|EU-0100038|FT-0655181|FT-0661360|SW199665-2|EN300-19606|A 5376|Acetylsalicylic Acid 1.0 mg/ml in Acetonitrile|C01405|D00109|E80792|Q18216|AB00051918-08|AB00051918_09|AB00051918_10|Arthritis Pain Formula Maximum Strength (Salt/Mix)|SR-01000075668-1|SR-01000075668-4|SR-01000075668-6|Acetylsalicylic acid, Vetec(TM) reagent grade, >=99%|Aspirin, British Pharmacopoeia (BP) Reference Standard|F2191-0068|Z104474430|Aspirin, United States Pharmacopeia (USP) Reference Standard|D41527A7-A9EB-472D-A7FC-312821130549|Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard|Acetylsalicylic acid, BioReagent, plant cell culture tested, >=99.0%|Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard|InChI=1/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12|11126-35-5|98201-60-6|Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material|Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.)
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 180.16 Topological Polar Surface Area 63.6
Heavy Atom Count 13 Rotatable Bond Count 3
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 4
PubChem CID
2244
Complexity
212
Formula
C9H8O4
Canonical SMILES
CC(=O)OC1=CC=CC=C1C(=O)O
InChI
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
InChIKey
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
IUPAC name
2-acetyloxybenzoic acid
Toxicity Properties of This DM
Documented Toxicity Properties
Toxicity Class Unreported
Predicted Toxicity Properties
Physical and chemical properties LogP

The log of the n-octanol/water distribution coefficient.

LogP possess a leading position with considerable impact on both membrane permeability and hydrophobic binding to macromolecules. Therefore, LogP is widely used in drug discovery and development as an indicator of potential utility of a solute as a drug.

The predicted logP of a compound in the range from 0 to 3 log mol/L will be considered proper.

1.237 TPSA

Topological polar surface area

In TPSA, PSA is estimated only from the syntype (topology) of atoms in the molecule, without considering the three-dimensional structure of the molecule, which is the origin of the name topological polar surface area.

The TPSA of a compound in the range from 0 to 140 will be considered proper, based on Veber rule.

63.6
Pfizer Rule: Accepted

Molecules with a high log P (>3) and low TPSA (<75) are likely to be toxic.

Pfizer infered the relationship between the physicochemical properties and toxicity of the drug from an animal tolerability (IVT) study dataset of 245 preclinical Pfizer compounds.Compounds with a high log P (>3) and low TPSA ( <75) are likely to be toxic.

(Bioorg Med Chem Lett. 18(17):4872-5. 2008)

Structural Characteristics ALARM NMR Rule

Molecules containing the reactivity-related thiol substructures are likely to be toxic.

The high-throughput screening (HTS) hit rate of reactive compounds was evaluated by NMR screening, X-ray crystallography and other biochemical and biophysical experiments, and then 75 thiol substructures for predicting reactivity were obtained by computational means for 2348 screening hit reactive compounds and 1156 reactive compounds obtained by La protein experiments.The molecule was matched to 75 reactivity-related substructures to obtain the information how many alarm groups the molecule contained and determine whether it was a thiol-reactive compound. Molecules with the thiol substructures are likely to be toxic.

(J Am Chem Soc. 127(1):217-24. 2005)

1 PAINS

Molecules containing the reactive substructures are likely to be toxic.

Pan Assay Interference Compounds (PAINS) is one of the most famous frequent hitters filters, which comprises 480 substructures derived from the analysis of FHs determined by six target-based HTS assay. By application of these filters, it is easier to screen false positive hits and to flag suspicious compounds in screening databases. One of the most authoritative medicine magazines Journal of Medicinal Chemistry even requires authors to provide the screening results with the PAINS alerts of active compounds when submitting manuscripts.

(J Med Chem. 45(1):137-42. 2002)

0
BMS Rule

Molecules containing the reactivity-related substructures are likely to be toxic.

BMS's primary HTS data over the past 12 years was evaluated and analyzed to determine the correlation of a group of compound functional groups with Promiscuity, defined as a drug that acts with multiple molecular targets and exhibits different pharmacological effects.

(J Chem Inf Model. 46(3):1060-8. 2006)

0 Chelator Rule

Molecules containing the substructures associated with metalloprotease targeting are likely to be toxic.

The chelate substructure fragment library (eCFL) for targeting metalloproteinases was prepared and its effectiveness in screening metalloproteinase inhibitors was verified by analysis and fluorescence-based assay experiments, and 55 substructures associated with metalloprotease targeting were finally determined as alert structures.

(ChemMedChem. 5(2):195-9. 2010)

0
Genotoxic Carcinogenicity Rule

Molecules containing the Genotoxic substructures are likely to be carcinogenic.

By constructing a molecular structure dataset containing the corresponding Ames test data (mutagens and non-mutagens). The substructure of the dataset is searched, and then the toxic substructure obtained by using chemical and mechanical knowledge and statistical criteria is derived, and the new toxic substructure is obtained and approved, and finally the reliability of the verification set is verified. Molecules containing these substructures may cause carcinogenicity or mutagenicity through genotoxic mechanisms.There are 117 substructures in this endpoint.

(J Med Chem. 48(1):312-20. 2005)

0 Non-genotoxic Carcinogenicity Rule

Molecules containing the NonGenotoxic substructures are likely to be carcinogenic.

Through the analysis and verification of the existing molecular library or the molecular library mined by data, the list of non-gene carcinogenic substructures (SA) is obtained according to the computerized data mining analysis, and finally the reliability of the substructure is verified. Molecules containing these substructures may cause carcinogenicity through nongenotoxic mechanisms. There are 23 substructures in this endpoint.

(Mutat Res. 659(3):248-61. 2008)

0
Toxicity Model Prediction hERG Blockers

The possibility of causing cardiotoxicity.

The human ether-a-go-go related gene. The During cardiac depolarization and repolarization, a voltage-gated potassium channel encoded by hERG plays a major role in the regulation of the exchange of cardiac action potential and resting potential. The hERG blockade may cause long QT syndrome (LQTS), arrhythmia, and Torsade de Pointes (TdP), which lead to palpitations, fainting, or even sudden death.So build a model by collecting a dataset to predict whether a compound is a hERG Blocker.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.015 (---) H-HT

The possibility of causing .hepatotoxicity.

The human hepatotoxicity. Drug induced liver injury is of great concern for patient safety and a major cause for drug withdrawal from the market. Adverse hepatic effects in clinical trials often lead to a late and costly termination of drug development programs.So build a model by collecting datasets to predict whether compounds will cause hepatotoxicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.258 (--)
DILI

The possibility of causing liver injury.

Drug-induced liver injury (DILI) has become the most common safety problem of drug withdrawal from the market over the past 50 years.So build a model by collecting datasets to predict whether compounds will cause liver injury.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.554 (+) CAMES Toxicity

The possibility of causing mutagenicity.

The Ames test for mutagenicity. The mutagenic effect has a close relationship with the carcinogenicity, and it is the most widely used assay for testing the mutagenicity of compounds.So build a model by collecting datasets to predict whether compounds will cause mutagenicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.013 (---)
Carcinogencity

The possibility of causing Carcinogencity.

Among various toxicological endpoints of chemical substances, carcinogenicity is of great concern because of its serious effects on human health. The carcinogenic mechanism of chemicals may be due to their ability to damage the genome or disrupt cellular metabolic processes. Many approved drugs have been identified as carcinogens in humans or animals and have been withdrawn from the market.So build a model by collecting datasets to predict whether compounds will cause Carcinogencity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.136 (--) Respiratory Toxicity

The possibility of causing Respiratory Toxicity.

Among these safety issues, respiratory toxicity has become the main cause of drug withdrawal. Drug-induced respiratory toxicity is usually underdiagnosed because it may not have distinct early signs or symptoms in common medications and can occur with significant morbidity and mortality.Therefore, careful surveillance and treatment of respiratory toxicity is of great importance.So build a model by collecting datasets to predict whether compounds will cause Respiratory Toxicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.266 (--)
Full List of Drug(s) That Produce This DM By Metabolism
NCX-4016 DR3242 Phase 2 Inflammation

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.